Molecular Pathology Laboratory
Understanding disease
                                One signal at a time....



Students' Material


Contact us
     TESTS OFFERED  Breast
 Colorectal cancer  Ewing's sarcoma Oligodendroglioma Cytogenetics    

Diagnostic Division

Breast cancer





Fluorescent in situ
hybridization for Breast cancer


Breast cancer: This is the commonest cancer in woman. Amplification of Her-2/neu oncogene on chromosome 17 is associated with aggressive breast cancer. However, These cancers are amenable to treatment with monoclonal antibody to HER-2 protein receptor. The monoclonal antibody is known as Herceptin and is given to patients with breast cancer, which have amplified Her-2 oncogene.
We use FDA approved systems to report on  the Her-2 gene status accurately in less than 2 days/case. Such quick and accurate reporting is important when time is so valuable.






BRCA1 and BRCA2 genes: The majority of breast and ovarian cancers are sporadic or not inherited. Germline mutations in the breast and ovarian cancer susceptibility genes BRCA1 (MIM 113705)and BRCA2 (MIM 600185) confer high risks of developing breast and ovarian cancers. Women with a mutation in the BRCA1 gene have a lifetime risk of 80-90 % of developing breast cancer and 40-65 % chance of developing ovarian cancer.

Our laboratory offers a level approach for sequencing BRCA1 and BRCA2 genes. To offer a comprehensive coverage we also employ MLPA for exon copy number determination.

In Kuwait, which is composed of young population, 40% of breast cancers inflict patients younger than 45 years of age. Of interest is that 70% of these are oestrogen receptor positive.  This is in contrast to beast cancers with defective BRCA1 or BRCA2 genes, which are usually oestrogen receptor negative.

    Our laboratory is currently conducting a population screening to identify breast cancer predisposing genes in our unique population. The availability of large consanguineous families with several affected individuals gives us a unique opportunity to do this.  

Standard operating protocol appeared here  and on request"Age-dependent penetrance of different germline mutations in BRCA1 gene"



    We now offer exome sequencing for breast cancer at a fraction of the cost of BRCA1 and 2 genes.
Please contact us for detail